Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
945 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01544179 | A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone(IMPRESS) | completed | Phase 3 | 265 | AstraZenecaINDUSTRY | 11 | Sep 25, 2020 | clinicaltrials |
| NCT02264574 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | completed | Phase 3 | 229 | Pharmacyclics LLC.INDUSTRY | 16 |
| Sep 21, 2020 |
| clinicaltrials |
| NCT03912389 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC(DOMAJOR) | unknown | Phase 3 | 292 | BiocadINDUSTRY | 6 | Sep 17, 2020 | clinicaltrials |
| NCT00625898 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab(BETH) | terminated | Phase 3 | 3,509 | NSABP Foundation IncNETWORK | 40 | Sep 10, 2020 | clinicaltrials |
| NCT00486512 | Chemoprevention of Colorectal Adenomas | terminated | Phase 3 | 350 | Colotech A/SINDUSTRY | 2 | Sep 3, 2020 | clinicaltrials |
| NCT01610284 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor(BELLE-2) | completed | Phase 3 | 1,147 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 25, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT02395172 | Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) | completed | Phase 3 | 792 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 29 | Aug 3, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT01450761 | Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone | completed | Phase 3 | 1,351 | Bristol-Myers SquibbINDUSTRY | 34 | Jul 8, 2020 | clinicaltrials |
| NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 1,276 | Eisai Inc.INDUSTRY | 23 | Jun 18, 2020 | clinicaltrials |
| NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | completed | Phase 3 | 365 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 18, 2020 | clinicaltrials |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | completed | Phase 3 | 1,289 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 18, 2020 | clinicaltrials |
| NCT01077518 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy(A+B) | terminated | Phase 3 | 346 | Novartis PharmaceuticalsINDUSTRY | 17 | Mar 27, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT00477282 | Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer | completed | Phase 3 | 509 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 5 | Mar 12, 2020 | clinicaltrials |
| NCT01569295 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )(Tugela) | completed | Phase 3 | 416 | Gilead SciencesINDUSTRY | 18 | Mar 10, 2020 | clinicaltrials |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | completed | Phase 3 | 1,886 | Hoffmann-La RocheINDUSTRY | 29 | Mar 6, 2020 | clinicaltrials |
| NCT01611090 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 3 | 578 | Janssen Research & Development, LLCINDUSTRY | 21 | Mar 3, 2020 | clinicaltrials |
| NCT00088530 | BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 3 | 140 | CTI BioPharmaINDUSTRY | 20 | Feb 5, 2020 | clinicaltrials |
| NCT01591122 | Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 313 | Janssen Research & Development, LLCINDUSTRY | 4 | Jan 21, 2020 | clinicaltrials |
| NCT01059630 | A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN) | completed | Phase 3 | 413 | Genentech, Inc.INDUSTRY | 14 | Jan 13, 2020 | clinicaltrials |
| NCT02272413 | Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 671 | Boehringer IngelheimINDUSTRY | 28 | Jan 13, 2020 | clinicaltrials |
| NCT00388726 | E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer | completed | Phase 3 | 762 | Eisai Inc.INDUSTRY | 17 | Jan 7, 2020 | clinicaltrials |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | completed | Phase 3 | 5,752 | GlaxoSmithKlineINDUSTRY | 12 | Jan 2, 2020 | clinicaltrials |
| NCT02008227 | A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy(OAK) | completed | Phase 3 | 1,225 | Hoffmann-La RocheINDUSTRY | 31 | Dec 20, 2019 | clinicaltrials |
| NCT00636168 | Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma | completed | Phase 3 | 1,211 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2019 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT02788279 | A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) | completed | Phase 3 | 363 | Hoffmann-La RocheINDUSTRY | 11 | Dec 11, 2019 | clinicaltrials |
| NCT02115386 | Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib(MACS1532) | terminated | Phase 3 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00844649 | Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas | completed | Phase 3 | 861 | CelgeneINDUSTRY | 11 | Nov 25, 2019 | clinicaltrials |
| NCT00622336 | A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | completed | Phase 3 | 330 | CelgeneINDUSTRY | 2 | Nov 20, 2019 | clinicaltrials |
| NCT01021423 | A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).(RENEW) | terminated | Phase 3 | 9 | CelgeneINDUSTRY | 12 | Nov 19, 2019 | clinicaltrials |
| NCT01324947 | Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma | completed | Phase 3 | 74 | CelgeneINDUSTRY | 15 | Nov 19, 2019 | clinicaltrials |
| NCT01249365 | The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | completed | Phase 3 | 199 | GlaxoSmithKlineINDUSTRY | 4 | Nov 13, 2019 | clinicaltrials |
| NCT00472303 | A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine | completed | Phase 3 | 622 | Grünenthal GmbHINDUSTRY | 16 | Nov 4, 2019 | clinicaltrials |
| NCT01264887 | Tapentadol in Chronic Malignant Tumour Related Pain | terminated | Phase 3 | 31 | Grünenthal GmbHINDUSTRY | 7 | Nov 4, 2019 | clinicaltrials |
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | completed | Phase 3 | 34 | GlaxoSmithKlineINDUSTRY | 7 | Oct 30, 2019 | clinicaltrials |
| NCT01030783 | A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma(TIVO-1) | completed | Phase 3 | 517 | AVEO Pharmaceuticals, Inc.INDUSTRY | 16 | Oct 28, 2019 | clinicaltrials |
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | completed | Phase 3 | 979 | Hoffmann-La RocheINDUSTRY | 31 | Oct 28, 2019 | clinicaltrials |
| NCT00825955 | Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment(BRISK PS) | completed | Phase 3 | 587 | Bristol-Myers SquibbINDUSTRY | 19 | Oct 9, 2019 | clinicaltrials |
| NCT02268045 | Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma | completed | Phase 3 | 272 | mAbxience Research S.L.INDUSTRY | 12 | Sep 26, 2019 | clinicaltrials |
| NCT00917384 | Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | completed | Phase 3 | 355 | Eli Lilly and CompanyINDUSTRY | 30 | Sep 25, 2019 | clinicaltrials |
| NCT01168973 | A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy | completed | Phase 3 | 1,253 | Eli Lilly and CompanyINDUSTRY | 27 | Sep 25, 2019 | clinicaltrials |
| NCT01419717 | Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer | completed | Phase 3 | 129 | AmgenINDUSTRY | 19 | Sep 24, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials